View Past PerformancePacific Edge バランスシートの健全性財務の健全性 基準チェック /66Pacific Edgeの総株主資本はNZ$10.7M 、総負債はNZ$0.0で、負債比率は0%となります。総資産と総負債はそれぞれNZ$17.6MとNZ$6.9Mです。主要情報0%負債資本比率NZ$0負債インタレスト・カバレッジ・レシオn/a現金NZ$7.78mエクイティNZ$10.66m負債合計NZ$6.94m総資産NZ$17.60m財務の健全性に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jul 02Pacific Edge Limited, Annual General Meeting, Aug 20, 2026Pacific Edge Limited, Annual General Meeting, Aug 20, 2026. Location: auckland New Zealandお知らせ • May 15Pacific Edge Limited has completed a Follow-on Equity Offering in the amount of NZD 25.4 million.Pacific Edge Limited has completed a Follow-on Equity Offering in the amount of NZD 25.4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 149,411,765 Price\Range: NZD 0.17 Transaction Features: Subsequent Direct Listingお知らせ • May 12Pacific Edge Limited to Report Fiscal Year 2026 Results on May 25, 2026Pacific Edge Limited announced that they will report fiscal year 2026 results at 10:00 AM, IDLE - International Date Line on May 25, 2026お知らせ • Nov 06Pacific Edge Limited to Report First Half, 2026 Results on Nov 25, 2025Pacific Edge Limited announced that they will report first half, 2026 results on Nov 25, 2025お知らせ • Jun 16Pacific Edge Limited, Annual General Meeting, Aug 06, 2025Pacific Edge Limited, Annual General Meeting, Aug 06, 2025. Location: auckland New Zealandお知らせ • Jun 03Pacific Edge Limited has completed a Follow-on Equity Offering in the amount of NZD 16 million.Pacific Edge Limited has completed a Follow-on Equity Offering in the amount of NZD 16 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 150,000,000 Price\Range: NZD 0.1 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,000,000 Price\Range: NZD 0.1 Transaction Features: Subsequent Direct Listingお知らせ • May 31Pacific Edge Limited has filed a Follow-on Equity Offering in the amount of NZD 5 million.Pacific Edge Limited has filed a Follow-on Equity Offering in the amount of NZD 5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 50,000,000 Price\Range: NZD 0.1お知らせ • May 30Pacific Edge Limited has filed a Follow-on Equity Offering.Pacific Edge Limited has filed a Follow-on Equity Offering. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: Subsequent Direct Listingお知らせ • May 12Pacific Edge Limited to Report Fiscal Year 2025 Results on May 30, 2025Pacific Edge Limited announced that they will report fiscal year 2025 results at 4:45 PM, IDLE - International Date Line on May 30, 2025お知らせ • Nov 06Pacific Edge Limited to Report First Half, 2025 Results on Nov 26, 2024Pacific Edge Limited announced that they will report first half, 2025 results on Nov 26, 2024お知らせ • May 07Pacific Edge Limited, Annual General Meeting, Sep 24, 2024Pacific Edge Limited, Annual General Meeting, Sep 24, 2024.お知らせ • May 01Pacific Edge Limited to Report Fiscal Year 2024 Results on May 21, 2024Pacific Edge Limited announced that they will report fiscal year 2024 results at 10:00 AM, NZST - New Zealand Standard on May 21, 2024お知らせ • Mar 14Pacific Edge Limited Announces Board ChangesPacific Edge Limited announced the retirement of Chair Chris Gallaher and Non-Executive Director Mark Green. Mr. Gallaher, who joined the Pacific Edge Board in July 2016, has resolved to reduce his governance commitments, and has indicated his intention to retire from the Board following the appointment of a successor and a structured handover at the end of this year. Meanwhile, with his family having made new commitments offshore, Mr. Green has notified the Board he does not intend to seek re-election at the company's next Annual Shareholders Meeting in September. Mr. Green joined the Pacific Edge Board in May 2021. The Board's Nomination Committee has commenced a process to appoint a new Chair and consider the recruitment of new Independent Directors.お知らせ • Oct 19Pacific Edge Limited to Report First Half, 2024 Results on Nov 23, 2023Pacific Edge Limited announced that they will report first half, 2024 results on Nov 23, 2023お知らせ • Jun 09Pacific Edge Limited Announces Medicare Coverage of Cxbladder Tests in the US Market is Expected to Cease from 17 July 2023Pacific Edge announces Medicare coverage of Cxbladder tests in the US market is expected to cease from 17 July 2023. This development follows the finalization of a Local Coverage Determination (LCD) (L39365) by Novitas, the Medicare Administrative Contractor (MAC) with jurisdiction for Pacific Edge's laboratory in Hershey Pennsylvania. The finalized LCD, which includes Cxbladder and tests provided by other companies, specifically notes the Cxbladder tests Triage, Detect, Monitor, Resolve and Detect+ as `not considered medically reasonable and necessary', the threshold required for coverage under the US Social Security Act. A number of other companies are also affected by the LCD. Over the coming days Pacific Edge will seek to explore all available legal options (including a potential appeal) with US-based lawyers, the key opinion leaders among customers, partners at The Coalition for 21st Century Medicine, and other impacted companies. Pacific Edge is currently unable to fully determine the impact of the new LCD on test volumes in the US market for the 2024 financial year. For the immediate future, the company will continue to promote Cxbladder and process all tests ordered by US clinicians whilst it further considers its strategy and future options. The company believes that in the short term it is prudent to continue to support Cxbladder as it determines the best path forward, but the approach will be accompanied by cost containment initiatives including, but not limited to an immediate hiring freeze and a halt on discretionary spending and new capital expenditure. In light of this new LCD, management and the Board at Pacific Edge are reviewing the scenario planning commenced last year to determine a strategic path forward that potentially includes: a) legal challenges or appeals, b) seeking to regain coverage through Novitas, c) seeking to be awarded coverage through an alternative MAC, d) alternative billing practices that would increase patient responsibility and e) remaining open to other strategic alternatives. Which of these the company adopts, will be determined by considering a number of factors including the potential impact on revenue, expenditure and cash reserves, the time and resources required to regain coverage, shareholder value implications, and the expected likelihood of success.New Risk • Jun 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$53.3m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (NZ$3.9m net loss in 3 years). Market cap is less than US$100m (US$53.3m market cap).財務状況分析短期負債: PFGT.Fの 短期資産 ( NZ$13.8M ) が 短期負債 ( NZ$6.8M ) を超えています。長期負債: PFGT.Fの短期資産 ( NZ$13.8M ) が 長期負債 ( NZ$126.0K ) を上回っています。デット・ツー・エクイティの歴史と分析負債レベル: PFGT.Fは負債がありません。負債の削減: PFGT.F 5 年前には負債がありませんでした。貸借対照表キャッシュ・ランウェイ分析過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。安定したキャッシュランウェイ: PFGT.Fは、前回報告された フリーキャッシュフロー に基づいて3か月分の十分な キャッシュランウェイ を有していますが、その後追加の資本を調達しました。キャッシュランウェイの予測: PFGT.Fフリーキャッシュフロー 推定値 に基づいて3か月間十分なキャッシュランウェイがあると予測されていますが、その後、追加の資本を調達しました。健全な企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/18 08:22終値2026/08/05 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Pacific Edge Limited 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関null nullBrookline Capital MarketsMaxim JacobsEdison Investment ResearchBenjamin CrozierForsyth Barr Group Ltd.3 その他のアナリストを表示
お知らせ • Jul 02Pacific Edge Limited, Annual General Meeting, Aug 20, 2026Pacific Edge Limited, Annual General Meeting, Aug 20, 2026. Location: auckland New Zealand
お知らせ • May 15Pacific Edge Limited has completed a Follow-on Equity Offering in the amount of NZD 25.4 million.Pacific Edge Limited has completed a Follow-on Equity Offering in the amount of NZD 25.4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 149,411,765 Price\Range: NZD 0.17 Transaction Features: Subsequent Direct Listing
お知らせ • May 12Pacific Edge Limited to Report Fiscal Year 2026 Results on May 25, 2026Pacific Edge Limited announced that they will report fiscal year 2026 results at 10:00 AM, IDLE - International Date Line on May 25, 2026
お知らせ • Nov 06Pacific Edge Limited to Report First Half, 2026 Results on Nov 25, 2025Pacific Edge Limited announced that they will report first half, 2026 results on Nov 25, 2025
お知らせ • Jun 16Pacific Edge Limited, Annual General Meeting, Aug 06, 2025Pacific Edge Limited, Annual General Meeting, Aug 06, 2025. Location: auckland New Zealand
お知らせ • Jun 03Pacific Edge Limited has completed a Follow-on Equity Offering in the amount of NZD 16 million.Pacific Edge Limited has completed a Follow-on Equity Offering in the amount of NZD 16 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 150,000,000 Price\Range: NZD 0.1 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,000,000 Price\Range: NZD 0.1 Transaction Features: Subsequent Direct Listing
お知らせ • May 31Pacific Edge Limited has filed a Follow-on Equity Offering in the amount of NZD 5 million.Pacific Edge Limited has filed a Follow-on Equity Offering in the amount of NZD 5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 50,000,000 Price\Range: NZD 0.1
お知らせ • May 30Pacific Edge Limited has filed a Follow-on Equity Offering.Pacific Edge Limited has filed a Follow-on Equity Offering. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: Subsequent Direct Listing
お知らせ • May 12Pacific Edge Limited to Report Fiscal Year 2025 Results on May 30, 2025Pacific Edge Limited announced that they will report fiscal year 2025 results at 4:45 PM, IDLE - International Date Line on May 30, 2025
お知らせ • Nov 06Pacific Edge Limited to Report First Half, 2025 Results on Nov 26, 2024Pacific Edge Limited announced that they will report first half, 2025 results on Nov 26, 2024
お知らせ • May 07Pacific Edge Limited, Annual General Meeting, Sep 24, 2024Pacific Edge Limited, Annual General Meeting, Sep 24, 2024.
お知らせ • May 01Pacific Edge Limited to Report Fiscal Year 2024 Results on May 21, 2024Pacific Edge Limited announced that they will report fiscal year 2024 results at 10:00 AM, NZST - New Zealand Standard on May 21, 2024
お知らせ • Mar 14Pacific Edge Limited Announces Board ChangesPacific Edge Limited announced the retirement of Chair Chris Gallaher and Non-Executive Director Mark Green. Mr. Gallaher, who joined the Pacific Edge Board in July 2016, has resolved to reduce his governance commitments, and has indicated his intention to retire from the Board following the appointment of a successor and a structured handover at the end of this year. Meanwhile, with his family having made new commitments offshore, Mr. Green has notified the Board he does not intend to seek re-election at the company's next Annual Shareholders Meeting in September. Mr. Green joined the Pacific Edge Board in May 2021. The Board's Nomination Committee has commenced a process to appoint a new Chair and consider the recruitment of new Independent Directors.
お知らせ • Oct 19Pacific Edge Limited to Report First Half, 2024 Results on Nov 23, 2023Pacific Edge Limited announced that they will report first half, 2024 results on Nov 23, 2023
お知らせ • Jun 09Pacific Edge Limited Announces Medicare Coverage of Cxbladder Tests in the US Market is Expected to Cease from 17 July 2023Pacific Edge announces Medicare coverage of Cxbladder tests in the US market is expected to cease from 17 July 2023. This development follows the finalization of a Local Coverage Determination (LCD) (L39365) by Novitas, the Medicare Administrative Contractor (MAC) with jurisdiction for Pacific Edge's laboratory in Hershey Pennsylvania. The finalized LCD, which includes Cxbladder and tests provided by other companies, specifically notes the Cxbladder tests Triage, Detect, Monitor, Resolve and Detect+ as `not considered medically reasonable and necessary', the threshold required for coverage under the US Social Security Act. A number of other companies are also affected by the LCD. Over the coming days Pacific Edge will seek to explore all available legal options (including a potential appeal) with US-based lawyers, the key opinion leaders among customers, partners at The Coalition for 21st Century Medicine, and other impacted companies. Pacific Edge is currently unable to fully determine the impact of the new LCD on test volumes in the US market for the 2024 financial year. For the immediate future, the company will continue to promote Cxbladder and process all tests ordered by US clinicians whilst it further considers its strategy and future options. The company believes that in the short term it is prudent to continue to support Cxbladder as it determines the best path forward, but the approach will be accompanied by cost containment initiatives including, but not limited to an immediate hiring freeze and a halt on discretionary spending and new capital expenditure. In light of this new LCD, management and the Board at Pacific Edge are reviewing the scenario planning commenced last year to determine a strategic path forward that potentially includes: a) legal challenges or appeals, b) seeking to regain coverage through Novitas, c) seeking to be awarded coverage through an alternative MAC, d) alternative billing practices that would increase patient responsibility and e) remaining open to other strategic alternatives. Which of these the company adopts, will be determined by considering a number of factors including the potential impact on revenue, expenditure and cash reserves, the time and resources required to regain coverage, shareholder value implications, and the expected likelihood of success.
New Risk • Jun 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$53.3m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (NZ$3.9m net loss in 3 years). Market cap is less than US$100m (US$53.3m market cap).